---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-347869"
form_type: "8-K"
ticker: "PBLS"
cik: "0001657677"
company_name: "Parabilis Medicines, Inc."
filed_at: "2026-08-13T11:19:04+00:00"
generated_at: "2026-08-13T11:20:15.993705+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Parabilis Q2 net loss $52.5M; $1.1B cash after $770.5M IPO; Regeneron deal up to $2.2B

## Summary
- Net loss $52.5M in Q2 2026 vs $34.8M prior year; R&D $39.4M, G&A $11.7M.
- Cash $1.1B as of June 30, 2026 (vs $27.7M Dec 31, 2025) after $770.5M IPO at $20.00/share; funds ops into 2030.
- Regeneron collaboration: $125M received ($50M upfront + $75M equity); up to $2.2B milestones plus low double-digit tiered royalties for Antibody-Helicon Conjugates.
- Zolucatetide: ESMO 2026 abstract accepted; FDA alignment Q4 2026; Phase 3 desmoid trial initiation H1 2027; FAP cohort H2 2026.
- Leadership: Helen Ho (Chief Business & Strategy Officer), Tom Kotarakos (CFO), Alan M. Sebulsky to Board.

## SEC filing metadata
- accession: 0001193125-26-347869
- form_type: 8-K
- ticker: PBLS
- cik: 0001657677
- company_name: Parabilis Medicines, Inc.
- filed_at: 2026-08-13T11:19:04+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1657677/000119312526347869/0001193125-26-347869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1657677/000119312526347869/ck0001657677-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-347869
- JSON: https://secwatch.observer/filing/0001193125-26-347869.json
- Plain text: https://secwatch.observer/filing/0001193125-26-347869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.